Document Detail

Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
MedLine Citation:
PMID:  19301987     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment. MAIN OUTCOME MEASURE: Resolution of endometrial thickening measured by transvaginal ultrasound at 3-month intervals; the response of metastases was assessed by standard oncological criteria. RESULTS: In all, 16 patients were studied. The BMI of 13 of the 16 patients was known and ranged from 20.7 to 47.7 (mean 34.5) kg/m(2). During treatment with AIs, mean endometrial thickness in the eight patients with EH decreased progressively by 81.7% from 14.7 mm at the start of treatment to 2.7 mm following 36 months of treatment. A greater original mean endometrial thickness of 17 mm was seen in the four patients with localised EA, this fell progressively by 67.1% to 5.6 mm following 36 months of treatment. No responses were seen in four patients with metastatic disease. CONCLUSION: Our results indicate that treatment of EH with anastrozole or letrozole can reduce endometrial thickness as seen ultrasonically, and that in some cases AI treatment can reduce endometrial thickness in patients with localised EA. We found no evidence to indicate that AI treatment prevents disease progression in patients with metastatic EA. Further investigations will be necessary to validate our findings from this small retrospective study and to compare AI inhibitor treatment with topical progestogen therapy.
L C Barker; I R Brand; S M Crawford
Related Documents :
15950667 - Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone...
12052587 - Five-year follow-up of endometrial ablation: endometrial coagulation versus endometrial...
18325517 - From oocyte to baby: a clinical evaluation of the biological efficiency of in vitro fer...
179897 - Tubal plastic surgery at the tel hashomer hospital: a critical study.
25351457 - Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthr...
19323927 - Long-term outcomes of drug-eluting versus bare-metal stent implantation in patients wit...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current medical research and opinion     Volume:  25     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-29     Completed Date:  2009-07-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  1105-9     Citation Subset:  IM    
Oncology Department, Airedale General Hospital, Steeton, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology,  therapeutic use
Aromatase Inhibitors / pharmacology*,  therapeutic use
Carcinoma / drug therapy*,  pathology
Disease Progression
Endometrial Hyperplasia / drug therapy*,  pathology
Endometrial Neoplasms / drug therapy*,  pathology
Endometrium / drug effects*,  pathology
Middle Aged
Neoplasm Metastasis
Nitriles / pharmacology*,  therapeutic use
Organ Size / drug effects
Retrospective Studies
Time Factors
Triazoles / pharmacology*,  therapeutic use
Reg. No./Substance:
0/Antineoplastic Agents; 0/Aromatase Inhibitors; 0/Nitriles; 0/Triazoles; 112809-51-5/letrozole; 120511-73-1/anastrozole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Breastmilk from allergic mothers can protect offspring from allergic airway inflammation.
Next Document:  Change in formulation and its potential clinical and pharmacoeconomic value: example of extended rel...